Holly Kordasiewicz

New Capabilities

As of July 2026: Co-developer of the drug's underlying technology

For decades, nearly every Alzheimer's drug that reached patients aimed at one target: a sticky protein called amyloid. On July 14, 2026, Biogen showed the first clinical evidence that hitting a different protein, tau, can also slow the disease.

Updated Jul 14